Dendreon Corporation (DNDN) (JOBS) Raises $356 Million for Manufacturing, Marketing of Prostate Cancer Drug  
12/11/2009 7:31:03 AM

Bookmark and Share

Xconomy -- Dendreon has just nailed down one of the biggest biotech financings in the U.S. this year. The Seattle-based biotech company (NASDAQ: DNDN) has secured $356 million for its quest to market the first treatment in the U.S. designed to actively stimulate the immune system to fight cancer cells like a virus.